A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
A Prospective, Single-arm Clinical Study of Bridging Allogeneic Stem Cell Transplantation After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in Relapsed/Refractory Ph-ALL and B-cell Lymphoma Patients
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Listed as NCT06087419, this PHASE1/PHASE2 trial focuses on Acute Lymphoblastic Leukemia and remains ongoing. Sponsored by Institute of Hematology & Blood Diseases Hospital, China, it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Oct 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute of Hematology & Blood Diseases Hospital, China
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.